Investment Team
Zeshan Muhammedi
Managing Partner
Washington, D.C.
Zeshan is a founder and Managing Partner of MBX Capital. He holds board roles at MBX partner companies Attivare Therapeutics, Cloudcath, Mae Health, AmacaThera, and SecureAire.
Previously, he was the CEO of FundRx, a healthcare and life sciences investment marketplace. Prior to FundRx, he was Managing Partner at Tensile Company, a venture advisory firm. At Tensile, he was an investor and advisor to plant genetics firm Ebbu, Inc (acquired in 2018 for $330mm) and worked with Torreya Partners, a life sciences investment bank, to launch AvaRx, an M&A research platform for the pharma industry.
He is an advisor to BrainMind, a consortium working to support advances in brain science. Zeshan earned his undergraduate degree from Emory University, and is a Kauffman Fellow.
Gurdane Bhutani
Managing Partner
New York, NY
Gurdane is a founder and Managing Partner of MBX Capital. He holds board roles at MBX partner companies Atlas Health, CareRev, Contraline, Freedom Biosciences, and Thesis.
Previously, he was the COO of FundRx, a healthcare and life sciences investment marketplace. Prior to FundRx, worked with private equity and corporate clients at Bain & Company and in public finance at Morgan Stanley. He has been an instructor on healthcare finance at the Cleveland Clinic Lerner College of Medicine and guest lecturer in the Wharton School's healthcare management program.
Gurdane earned an MPH in Epidemiology and Environmental Health Sciences from Yale University’s School of Public Health, where he was a Trowell-Harris Scholar. At Yale, he conducted research on the applications of human organoids and organ-chips in predictive toxicology. He earned his undergraduate degrees in Computer Science and Public Policy from Duke University, where he was an A.B Duke Scholar. He was a Lord Rothermere Scholar at the University of Oxford and is a Kauffman Fellow.
Martin Gargaros
Director
New York, NY
Martin is a Director on the MBX team, focusing on new investments across environmental health and life sciences, in addition to portfolio management, firm operations and investor relations.
Martin was previously Director in Strategic Finance at V3 Commodities Group, a private credit company where he worked on a variety of credit and growth capital transactions with energy providers.
Prior to V3, he worked in Strategic Finance at Roivant Sciences, where he worked on the company’s $3B strategic alliance with Sumitomo Dainippon, covering multiple therapeutic areas including women’s health, urology, immunology, cardiopulmonlogy, and gene therapy.
Martin is a CFA charterholder, and earned graduate degrees in Management Science & Engineering at Columbia University and Mechanical & Industrial Engineering at Arts et Métiers ParisTech, in addition to his undergraduate degree in Applied Economics from Université Paris Dauphine.